Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):414–418. doi: 10.1097/QAI.0000000000000190

Table 1.

Participant characteristics from the Botswana-Baylor Children's Clinical Center of Excellence (n=78).

Mean (SD) Median & (IQR)
Child age (years) 3.9 (1.3) 4.0 (3.0, 5.0)
CD4% 32.8 (9.4) 33.3 (27.6, 38.0)
BMI z-score −0.6 (1.4) −0.7 (−1.6, 0.45)
Weight for height z-score −0.8 (1.4) −0.7 (−1.7, 0.2)
Height for age z-score −1.6 (1.4) −1.7 (−2.3, −0.9)
Days on newest ARV medication 1058 (623) 1033 (665, 1393)
Household wealth score 5.4 (2.1) 5.0 (4.0, 7.0)
HFIAS summed score 6.8 (5.9) 7.0 (1.0, 10.0)

n (%)

Child gender
    Female 33 (42.3)
    Male 45 (57.7)
Orphan status
    Both parents alive 66 (84.7)
    One or both parents deceased 12 (15.4)
Household income (Pula)
    0-1500 10 (12.8)
    >1500 – 3000 62 (79.5)
    >3000 6 (7.7)
Parent highest education
    Primary school (1-7th grade) 8 (10.3)
    Junior secondary (8-10th grade) 44 (56.4)
    Senior secondary (11-12th grade) 21 (26.9)
    University (≥13th grade) 5 (6.4)
Food assistance
    Yes 22 (28.2)
    No 56 (71.8)
Household location
    Village/rural 44 (56.4)
    City 34 (43.6)
ARV therapy
    Two tablet ARV regimen 22 (28.2)
    Three tablet ARV regimen 56 (71.8)

Key: ARV = Antiretroviral therapy; HFIAS = Household Food Insecurity Assess Scale; SD = Standard Deviation; 3000 Pula is less than approximately 344 US dollars